Drug Trial Radar · NCT07498478
Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment
Last checked: Nov 19, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
94
Planned (sponsor's estimate)
Start
Mar 17, 2026
Primary completion
Jun 30, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- TransThera Sciences (Nanjing), Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if tinengotinib combined with fulvestrant works to treat patients with HR-Positive and HER-2-Negative or low-expressing advanced breast cancer. It will also learn about the safety of combination therapy. The main questions it aims to answer are: 1. Does tinengotinib combined with fulvestrant reduce the tumor burden in participants? 2. What medical problems do participants have when taking the combination therapy? Participants will: Take tinengotinib and fulvestrant to find the optimal dose of tinengotinib for the combination therapy in Part A. In Part B, will take tinengotinib at the optimal dose with fulvestrant or tinengotinib alone to see if the combination therapy works better than tinengotinib monotherapy.
Conditions
- Breast Cancer
Interventions
Tinengotinib at the optimal dose combined with FulvestrantDrug
Participants will receive tinengotinib at the optimal dose once daily with fulvestrant in 28-day cycles per protocol defined schedule.
TinengotinibDrug
Participants will receive tinengotinib once daily in 28-day cycles per protocol defined schedule.
tinengotinib combined with fulvestrantDrug
Participants will take tinengotinib at the starting dose of 10 mg once daily with fulvestrant to determine the optimal dose of tinengotinib in combination with fulvestrant. If not tolerated, the dose of tinengotinib will be reduced to 8 mg or 6 mg once daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: safety evaluation parametersTime frame: From signing of the informed consent until 28 days after the last dose or the end of the study (whichever occurs first), an average of 1 year.
- Part B: Objective Response Rate (ORR) (RECIST v1.1)Time frame: From first study drug administration to the end of treatment, an average of 1 year.
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
Cancer Hospital, Chinese Academy of Medical Sciences
Beijing, China · Recruiting
Beijing Cancer Hospital
Beijing, China · Not yet recruiting
The First Medical Center, Chinese PLA General Hospital
Beijing, China · Not yet recruiting
Southwest Hospital
Chongqing, China · Not yet recruiting
Fudan University Shanghai Cancer Center
Shanghai, China · Not yet recruiting
Tianjin Medical University Cancer Institute & Hospital
Tianjin, China · Not yet recruiting
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China · Not yet recruiting
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China · Not yet recruiting
Hunan Cancer Hospital
Changsha, Hunan, China · Not yet recruiting
Jiangsu Province Hospital
Nanjing, Jiangsu, China · Not yet recruiting
Shandong Cancer Hospital
Jinan, Shandong, China · Not yet recruiting
Linyi Cancer Hospital
Linyi, Shandong, China · Recruiting
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.